Franco-Belgian deal seeks 'synergistic drug combinations'

9 March 2017

France’s neurodegenerative diseases specialist Pharnext SA (FR00111911287 - ALPHA) has announced a research and development (R&D) agreement with Belgium-based biotech Galapagos (Euronext: GLPG) to generate an additional pipeline of synergistic drug combinations in a broad set of indications.

The agreement seeks to utlilze both partners' R&D capabilities though it will initially be based on Pharnext's disruptive technological platform, Pleotherapy.

For a given new preclinical or clinical candidate drug provided by Galapagos, Pharnext's technology will aim to identify already approved drugs which could be combined at low doses with this new candidate in order to safely increase its efficacy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK